Deubiquitinase OTUD5 as a novel protector against 4-HNE-triggered ferroptosis in myocardial ischemia/reperfusion injury
OMahony SM, Marchesi JR, Scully P, Codling C, Ceolho AM, Quigley EM, et al
Patients with certain genetic profiles may tolerate higher doses faster or experience nausea at lower concentrations
Available at: 63 BulchandaniDNachnaniJSHerndonBMolteniAPathanMHQuinnTet al
Insurance and Prior Authorization Even if you meet FDA criteria, insurance often adds hoops: Documented lifestyle intervention often 3-6 months of supervised diet, exercise, and behavior change before authorization Step therapy requiring failure of older agents like phentermine or orlistat BMI documentation requiring recent clinical measurement, not self-report Specific comorbidity documentation lab values, imaging, or specialist notes Renewal criteria demonstrating sustained weight loss (often 5% at 6-12 months) for continued coverage Many plans explicitly exclude "drugs used for weight loss" regardless of FDA labeling
All the evidence related to cuproplasia and cuproptosis is derived from retrospective studies, with only the association between reduced copper levels and a higher risk of lung cancer stemming from a meta-analysis of retrospective data
